New drug shows promise for Tough-to-Treat ovarian cancer
NCT ID NCT05043922
First seen Jan 10, 2026 · Last updated May 21, 2026 · Updated 18 times
Summary
This study tests a new drug called CYH33 in 93 women whose ovarian, fallopian tube, or peritoneal clear cell cancer has returned or not gone away. The drug targets a specific genetic change (PIK3CA mutation) to try to shrink tumors. Participants must have already tried standard chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Obstetrics and Gynecology Hospital, Capital Medical University
Beijing, China
-
Chinese PLA General Hospital
Beijing, China
-
Harbin Medical University Cancer Hospital
Harbin, China
-
Hokkaido University Hospital
Sapporo, Japan
-
Hubei Cancer Hospital
Hubei, China
-
Hunan Cancer Hospital
Hunan, China
-
Jiangsu Province Hospital
Nanjing, China
-
Jikei University Hospital
Minato-Ku, Tokyo, Japan
-
Keio University Hospital
Shinjuku-Ku, Tokyo, Japan
-
Kurume University Hospital
Kurume, Fukuoka, Japan
-
Nagoya University Hospital
Nagoya, Japan
-
National Cancer Center Hospital
Chuo Ku, Tokyo, Japan
-
Niigata University Medical & Dental Hospital
Niigata, Japan
-
Obstetrics & Gynecology Hospital of Fudan University
Shanghai, China
-
Okayama University Hospital
Okayama, Japan
-
Osaka University Hospital
Suita, Osaka, Japan
-
Qilu Hospital of Shandong University
Jinan, China
-
Qingdao Central Hospital
Qingdao, China
-
Shanghai First Maternity and Infant Hospital
Shanghai, China
-
Shikoku Cancer Center
Matsuyama, Japan
-
Sir Run Run Shaw Hospital， School of Medicine, Zhejiang University
Zhejiang, China
-
Sun Yat-sen University Cancer Center
Guangdong, China
-
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
-
The First Affiliated Hospital of Hainan Medical College
Haikou, China
-
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
-
The First Affiliated Hospital, Sun Yat-sen University
Guangdong, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
-
The People's Hospital Of Guangxi Zhuang Autonomous Region
Nanning, China
-
The Southwest Hospital of AMU
Chongqing, China
-
The Third People's Hospital of Hainan Province
Hainan, China
-
Tianjin Medical University General Hospital
Tianjin, China
-
Tohoku University Hospital
Sendai, Japan
-
West China Second University Hospital, Sichuan University
Sichuan, China
-
Xiaohua wu
Shanghai, China
-
Zhejiang Cancer Hospital
Hangzhou, China
-
Zhongnan Hospital of Wuhan University
Wuhan, China
Conditions
Explore the condition pages connected to this study.